Diclofenaco dietilamonio

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Diclofenaco dietilamonio

Quick Facts

Property Description
Active ingredient Diclofenac (as the diethylamine salt)
Form Topical Gel, Cream, or Emulgel
Pharmacological class Non-steroidal Anti-inflammatory Drug (NSAID)
Common purpose Localized relief of pain and inflammation
Origin Synthetic, Phenylacetic Acid Derivative

What Type of Medicine is Diclofenaco dietilamonio?

Diclofenaco dietilamonio is the specific chemical salt form of the potent anti-inflammatory drug Diclofenac, and it belongs to the widely recognized pharmacological class of Non-steroidal anti-inflammatory drugs (NSAIDs). This compound is a synthetic Phenylacetic acid derivative that functions as an analgesic and anti-inflammatory agent. Its general effectiveness in managing localized soft-tissue discomfort is clinically recognized and supported by pharmacological studies.

The core active component is Diclofenac, while the diethylamine is a crucial counter-ion chemically added to the formula. This specific salt is a key differentiator because it is formulated solely to optimize penetration and stability, ensuring its efficient delivery when prepared for topical use, making it distinct from other Diclofenac salts formulated for systemic oral absorption.


Why is Diclofenaco Diethylamine Formulated as a Topical Gel?

This medicine is most commonly presented in a topical dosage form, such as a gel, cream, or emulgel, and its exclusive route of administration is dermal application. The specialized topical gel base is a critical component that facilitates the absorption of the active ingredient, Diclofenac diethylamine, directly through the skin surface.

The purpose of the topical formulation is to allow for a focused delivery of the single active ingredient to the local area where it is applied. This method is utilized to maximize the therapeutic concentration at the affected site, providing a concentrated effect while minimizing the level of drug distributed throughout the entire body. This localized action profile is the primary advantage of this preparation.


What is the General Purpose of This NSAID Preparation?

The general purpose of this specific NSAID preparation is to provide effective, localized relief from the primary symptoms of inflammation and pain. It is classified as an anti-inflammatory agent and analgesic due to its ability to modulate the body's pain signals.

At a fundamental level, the Diclofenac moiety works by inhibiting the synthesis of prostaglandins, which are the chemical messengers released by damaged tissue that signal and perpetuate swelling and pain. By reducing the concentration of these inflammatory chemicals locally, the medication helps to relieve the discomfort and physical restriction that typically accompany inflammatory conditions.

Regulatory References

  1. as noted in NIH StatPearls reviews

What side effects are possible with Diclofenaco dietilamonio?

Possible Side Effects and Safety Information

The safety profile for Diclofenaco dietilamonio, a topical Non-steroidal Anti-inflammatory Drug (NSAID), is primarily characterized by localized effects at the application site. The documentation of adverse reactions is classified by frequency and system-organ class in regulatory sources.


Adverse Reaction Classifications

Classification Examples of Reactions Frequency System-Organ Class
Localized Skin Reactions Skin rash, pruritus (itching), erythema, dermatitis (including contact dermatitis), eczema Common (1 in 10 to 1 in 100 users) Skin and Subcutaneous Tissue Disorders
Serious Systemic Reactions Hypersensitivity reactions (angioedema, anaphylaxis), asthma, photosensitivity reactions Very Rare (fewer than 1 in 10,000 users) Immune System Disorders, Respiratory Disorders

Safety Considerations and Constraints

The regulatory profile mandates consideration of high-level constraints for certain individuals. Diclofenaco dietilamonio is contraindicated in individuals with known hypersensitivity to diclofenac, aspirin, or other NSAIDs. Application to open wounds, infected skin, mucous membranes, or near the eyes is also restricted.

While systemic exposure is minimal, regulatory sources note that the risk of systemic NSAID-associated adverse reactions (e.g., gastrointestinal or renal effects) is increased by application over extensive skin areas, prolonged treatment, or the use of occlusive dressings. Special considerations apply to patients with a history of asthma or severe renal or hepatic impairment, as noted in the official labeling.

Overdose and Emergency Response

The official regulatory profile for Diclofenac diethylamine topical gel establishes that an overdose resulting from application to the skin is very unlikely due to the drug's low systemic absorption. If the recommended topical dose is significantly exceeded, the official instruction is to simply remove the excess gel and wash the area off with water.

The primary overdose concern addressed in regulatory labeling is accidental oral ingestion of the gel. This scenario can result in systemic effects similar to an overdose of oral Non-steroidal Anti-inflammatory Drugs (NSAIDs). The documented clinical manifestations following ingestion may include gastrointestinal symptoms such as nausea, vomiting, epigastric pain, and central nervous system effects such as confusion, dizziness, and convulsions (seizures).

Severe outcomes linked to systemic Diclofenac exposure are also noted in the regulatory documents. These include potentially life-threatening complications such as acute renal failure, metabolic acidosis, serious gastrointestinal bleeding or perforation, and serious cardiovascular thrombotic events (myocardial infarction or stroke).

Due to the risk of significant systemic adverse effects following ingestion, immediate medical attention is required. Management relies on general therapeutic measures adopted for NSAID poisoning, such as the consideration of gastric lavage and the use of oral activated charcoal. Regulatory information explicitly states that no specific antidote exists for Diclofenac poisoning.

Therapeutic Uses of Diclofenaco dietilamonio

Quick Facts: Diclofenaco dietilamonio

  • Therapeutic Domain: Pain management and relief from joint swelling.
  • Primary Uses: Managing signs and symptoms associated with localized arthritis pain.
  • Specific Conditions: Used to address pain linked to minor strains, sprains, and contusions.

Diclofenaco dietilamonio, typically available in a topical formulation such as a gel, is used to help manage localized pain and swelling. It is generally applied to the affected area to offer symptom relief for conditions impacting the musculoskeletal system.

Its therapeutic action supports the temporary relief of discomfort associated with various forms of localized arthritis, particularly in joints like the knees, hands, and ankles. This medication may also provide temporary relief from acute pain caused by common injuries, including minor muscle strains, sprains, and bruising (contusions). It is a topical option that can be considered for the management of joint-related tenderness and stiffness.

Regulatory References

  1. NIH MedlinePlus guidance

Eligibility and Restrictions for Use

Eligibility Profile: Who Can and Cannot Use Diclofenaco Dietilamonio

Eligibility for Diclofenaco dietilamonio (topical diclofenac) is strictly governed by regulatory guidelines, primarily focusing on hypersensitivity, age, and physiological state.

Absolute Contraindications (Must Not Use):

  • NSAID Allergy: Individuals with a history of asthma, urticaria, or severe allergic-type reactions (e.g., bronchospasm) precipitated by aspirin or any other Nonsteroidal Anti-inflammatory Drug (NSAID).
  • Pregnancy: Females in the third trimester of pregnancy (starting at 30 weeks gestation) due to risk of fetal harm.
  • Age Restriction: Children and adolescents under 14 years of age (in many markets) due to insufficient data on efficacy and safety.
  • Application Site: Must not be applied to non-intact, damaged, or infected skin, open wounds, or burns.

Restricted/Conditional Use:

  • Pregnancy (First/Second Trimester) and Lactation: Use is generally not recommended or should be avoided unless clearly necessary and with minimal dosage, due to potential risks.
  • Comorbidities: Patients with severe, advanced conditions, such as severe heart failure or advanced renal disease, are advised to avoid use unless a healthcare provider determines the benefits outweigh the risks.

Use is approved for adults and adolescents aged 14 and over who do not have any contraindications.

What should I know about interactions with other medicines?

Diclofenaco dietilamonio Interactions with Other Medicines and Products

Due to the low systemic absorption of Diclofenaco dietilamonio when applied topically as a gel, the likelihood of conventional drug interactions is generally considered low. However, official regulatory documents list potential interactions based on the known risks of the systemic NSAID component, Diclofenac.

Documented Interactions and Restrictions

Contraindicated Combinations

The use of this medication is contraindicated for the management of peri-operative pain following Coronary Artery Bypass Graft (CABG) surgery. Additionally, concomitant use with oral Non-steroidal Anti-inflammatory Drugs (NSAIDs) or analgesic doses of Aspirin is not generally recommended to avoid potential cumulative adverse effects.

Interactions Requiring Monitoring

Diclofenaco dietilamonio may interact with systemic medications, necessitating monitoring by a healthcare provider:

  • Anticoagulants: Increased risk of hemorrhage requires close monitoring of blood coagulation.
  • ACE Inhibitors/ARBs/Diuretics: May diminish the anti-hypertensive or diuretic effects. Monitoring of blood pressure and diuretic efficacy is required.
  • Digoxin, Lithium, and Methotrexate: May increase the plasma concentration and potential toxicity of these agents, requiring monitoring of their serum levels.

Population-Specific Cautions

In elderly, volume-depleted, or renal-impaired patients, co-administration with ACE Inhibitors or ARBs may increase the risk of deterioration of renal function, requiring specific monitoring.

Mechanism of Action

Inhibition of the Cyclooxygenase ( COX) Enzyme System

The primary mechanism of Diclofenac involves its role as a competitive inhibitor of the Cyclooxygenase (COX) enzymes, particularly the inducible COX-2 isoform. This action inhibits the biosynthesis of Prostanoids, such as Prostaglandin E2 ( PGE2), which are key chemical mediators involved in the local inflammatory signaling cascade.


Modulation of Peripheral Pain Receptor Sensitization

By suppressing the production of PGE2 at the tissue level, the drug directly interferes with the signaling that lowers the activation threshold of peripheral nociceptors (pain receptors). This mechanism limits the chemical hypersensitivity of the nerve endings, which is the physiological consequence that results in modulation of the peripheral nociceptive signal.


Pharmaceutical Mechanism for Targeted Delivery

The addition of the diethylamine salt is a specialized pharmaceutical mechanism that ensures the active Diclofenac molecule is effectively driven across the skin barrier into the underlying tissue. This formulation step facilitates the local availability of the drug by promoting percutaneous absorption, ensuring the core COX inhibition mechanism can occur in the targeted tissue at a sufficient concentration.

Dosage and Administration Information

Official Administration Guidelines

Diclofenaco dietilamonio is officially approved for Cutaneous Use (Topical/Dermal), where the gel is applied directly to the skin over the affected area. The official use protocol requires utilizing the lowest effective dosage for the shortest duration necessary for the intended purpose. The specific dosing schedule is highly dependent on the formulation's strength and the targeted condition.


Dosage and Frequency

Doses must be accurately measured using a dosing card or applicator supplied with the product to ensure proper administration.

The 1% gel for osteoarthritis pain specifies a dose of 2 grams for upper extremities or 4 grams for lower extremities per joint, typically applied four times daily (QID). The 2% gel for acute pain often requires 2 to 4 grams per application, usually applied two times daily (BID). A strict maximum daily dose must not be exceeded, which is generally 32 grams for the 1% gel and 8 grams for the 2% gel.


Duration and Special Conditions

For acute soft tissue injuries, the treatment should generally not exceed seven days without a medical review. The gel must only be applied to intact, non-diseased skin and must not be used under an airtight occlusive dressing. After application, patients are instructed to wash hands immediately (unless treating the hands) and avoid showering or bathing for at least 30 to 60 minutes. No routine dose adjustment is specified for older adults or patients with minor renal or hepatic impairment due to the formulation's low systemic absorption.

Recent Clinical Evidence

Research Evidence: Overview of Studies for Diclofenaco Dietilamonio

The research base for Diclofenaco dietilamonio topical formulations is primarily derived from clinical trials that evaluate its localized application. This overview describes the structure of the available research, focusing only on what the studies explored and the populations that were observed.


Evidence for Localized Osteoarthritis (OA) Pain

The evidence for use in localized osteoarthritis (OA) was studied in numerous Randomized Controlled Trials (RCTs), with the findings later consolidated through large-scale Systematic Reviews and Meta-analyses. These studies primarily included Adults and older adults who had a diagnosis of mild to moderate OA, with research concentrating on the knee and hand joints. Research explored outcomes related to physical discomfort, daily functioning, and symptom intensity, using standardized patient-reported outcomes describing perceived discomfort.

Studies monitored changes measured during the study period for outcomes reflecting daily functioning, such as the WOMAC physical function scores, over intermediate study durations, typically ranging from 6 to 12 weeks. The evidence contributes to understanding symptom patterns, with the body of data being categorized as having a High level of consistency for the outcomes studied.


Evidence for Acute Localized Musculoskeletal Injuries

Diclofenaco dietilamonio was studied for conditions associated with acute or disruptive episodes, such as minor sprains, strains, and contusions. The research utilized Placebo-Controlled RCTs to evaluate the medicine for these acute, short-term conditions. Study populations included Adults and adolescents (age 14 and older), and the trials were conducted during periods of increased symptom activity, primarily focusing on short-term symptom changes over periods typically ranging from 2 to 14 days. Research monitored outcomes describing episodic or acute changes in pain on movement (POM) and pain at rest (PAR).

Studies report how symptoms evolved in the observed populations during the defined time intervals. The evidence is assessed as having a High level of certainty and consistency for the acute, short-term outcomes related to these localized injuries.


Gaps and Uncertainties in the Research Evidence

Long-term effects are not fully established beyond the periods observed in the clinical trials, as follow-up durations were limited. Research is ongoing, but evidence is limited regarding the use of the topical formulation for joints other than the knee and hand. Comparative evidence is lacking for certain alternative treatments, and findings describe group patterns, not personal outcomes.

Key Studies & References

  1. Diclofenac Topical (NIH MedlinePlus Drug Information)
  2. Diclofenac Topical (NIH StatPearls Review)

Frequently Asked Questions (FAQ)

Common questions about Diclofenaco dietilamonio (FAQ)


Q: What is the main purpose of using Diclofenaco dietilamonio gel?

The medicine is indicated for the treatment of pain associated with localized joint conditions like osteoarthritis. It is also approved for the local symptomatic relief of pain and inflammation in acute soft tissue injuries such as sprains and strains, according to official regulatory information.


Q: What types of pain is Diclofenaco dietilamonio typically used for?

It is typically used for localized joint pain from conditions like osteoarthritis and for temporary relief of pain and inflammation from acute injuries, including sprains, strains, or bruises, according to official labeling.


Q: Why do some people use Diclofenaco dietilamonio for conditions other than arthritis?

The primary approved uses are for localized osteoarthritis pain and acute soft tissue injuries. Regulatory bodies have also approved certain topical diclofenac formulations for a skin condition called actinic keratosis. This accounts for its use in conditions beyond joint pain.


Q: Is Diclofenaco dietilamonio considered a steroid or an NSAID?

Diclofenaco dietilamonio is officially classified as a Nonsteroidal Anti-inflammatory Drug (NSAID). Official regulatory documents confirm that it is not a steroid.


Q: What is the difference between diclofenac diethylamine and diclofenac sodium?

Diclofenac diethylamine is a salt formulation specifically used in topical gels to help the active medicine penetrate the skin. Diclofenac sodium is the common salt used in oral medications that provide systemic treatment.


Q: Can people with a history of asthma or aspirin-related sensitivity use this medicine?

The medicine is contraindicated for use in individuals who have experienced asthma attacks, hives, or allergic-type reactions after taking aspirin or other NSAIDs, as stated in official regulatory documents.


Q: What pre-existing medical conditions might prevent someone from being eligible to use the gel?

The product information notes that the medicine is contraindicated in patients with a known history of allergic reactions to aspirin or other NSAIDs, and for pain management following Coronary Artery Bypass Graft (CABG) surgery. Cautions are also noted for patients with a history of heart failure or gastrointestinal bleeding.


Q: Is Diclofenaco dietilamonio safe for use in older adults (people over 65)?

Regulatory information states that no special dose adjustment is usually necessary for older adults. However, official warnings note that older adults are generally at greater risk for certain serious side effects, such as gastrointestinal bleeding or kidney problems, when using NSAIDs.


Q: Can pregnant women or those who are breastfeeding use Diclofenaco dietilamonio gel?

Regulatory documents state that the use of NSAIDs like Diclofenaco is contraindicated starting at 30 weeks gestation due to potential fetal risks. For breastfeeding, use is generally not recommended, and the official label specifies the gel must not be applied to the breast area.


Q: Is it possible for Diclofenaco dietilamonio gel to cause stomach problems like ulcers or bleeding?

Official warnings indicate that NSAIDs carry a potential risk of serious gastrointestinal issues, including bleeding and ulceration. This risk is generally considered low with the topical gel due to low systemic absorption. However, the risk is noted, especially when the gel is applied over large areas of the body or for long periods.


Q: Can Diclofenaco dietilamonio affect heart health or increase the risk of stroke?

Official warnings indicate that NSAIDs, including this topical formulation, may increase the risk of serious cardiovascular thrombotic events, such as heart attack and stroke. This potential risk is noted to occur early during the treatment period.


Q: Can Diclofenaco dietilamonio cause changes in blood pressure?

Regulatory documents indicate that NSAIDs have been associated with fluid retention. In some cases, this may lead to the development of new high blood pressure or the worsening of existing high blood pressure.


Q: What are the most common skin reactions at the site where the gel is applied?

Common localized skin reactions reported in regulatory documents include redness, itching, rash, dryness, scaling, and irritation at the application site. These are localized side effects.


Q: Is it normal to feel a mild burning or itching sensation when first using the product?

Official safety information notes that local reactions such as mild burning, itching, or redness at the application site are among the common effects reported during use.


Q: What are the signs of a severe allergic reaction to Diclofenaco dietilamonio?

Severe reactions, noted in regulatory documents, can include symptoms of an allergic reaction such as hives, difficulty breathing, or swelling of the face, lips, tongue, or throat. Serious skin conditions have also been reported.


Q: Can the gel cause side effects in other parts of the body, such as dizziness or headaches?

Although the medicine's systemic absorption is low, regulatory documents note that it may rarely cause systemic effects. These include central nervous system effects such as headache, dizziness, or drowsiness.


Q: How long does it usually take to start feeling pain relief after applying the gel?

Regulatory documents do not provide a specific time for the first sensation of pain relief. Clinical studies for some approved conditions have assessed the full effectiveness after up to seven days of consistent use.


Q: Why is it advised not to apply heat or cover the area with a bandage after application?

Official administration guidelines state that the gel must not be used under an airtight, occlusive dressing or with external heat. This instruction is connected to the potential for increased absorption of the medicine through the skin, which may raise the risk of systemic side effects.


Q: Is it dangerous if the gel accidentally gets into the eyes, nose, or mouth?

Regulatory instructions strictly state that the gel must not come into contact with the eyes or any mucous membranes (such as the mouth or nose). The gel should also not be ingested.


Q: Does using the gel cause sensitivity to sunlight or make a person sunburn more easily?

Official safety information notes that the medicine may cause photosensitivity reactions, meaning an increased skin sensitivity to light. Regulatory bodies advise caution regarding sun and artificial UV exposure during use.


Q: What are the guidelines regarding sun exposure after applying the gel?

Regulatory bodies state that exposure of the treated area to natural or artificial sunlight should be limited or avoided. This is because the medicine may increase the skin's sensitivity to light (photosensitivity).


Q: Is there a risk of interaction if alcohol is consumed while using the topical gel?

Regulatory warnings advise against the concurrent ingestion of alcohol with NSAIDs. This is because alcohol can increase the risk of gastrointestinal bleeding or irritation associated with the NSAID component.


Q: Does using the gel affect the effectiveness of birth control pills?

Highly authoritative sources state that diclofenac is not known to affect the effectiveness of hormonal contraceptives, including the combined pill or the progestogen-only pill.


Q: What is the correct way to store Diclofenaco dietilamonio gel?

Storage guidelines typically recommend keeping the gel in its original container, tightly closed, at room temperature. The container should also be stored out of reach of children.


Q: What does the research evidence indicate about the effectiveness of topical diclofenac versus a placebo?

The effectiveness of the gel for its approved uses is supported by data from regulatory clinical trials that compared the gel against a placebo (an inactive substance). These trials showed superiority over the placebo for treating the indicated conditions.

How should Diclofenaco dietilamonio be stored and disposed of?

How to Store and Dispose of Diclofenac Diethylamine Gel

Storage and disposal of this medication must adhere strictly to the conditions detailed in the official regulatory labeling.


Official Storage Requirements

Condition Regulatory Rule
Temperature Store below 30 C (or 25 C for some forms). Do not freeze.
Protection Keep in the original tube and protect from light and moisture.
Child Safety Must be kept out of the sight and reach of children.
Stability Use within the officially stated period after opening (e.g., 28 days or 6 months), depending on the specific product.

Disposal

Any unused or expired product must be disposed of in accordance with local regulations. Diclofenac poses a risk to the aquatic environment, therefore, proper disposal is mandatory to avoid contamination of water sources.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Diclofenaco dietilamonio found in:

A-Z Index: